


Nizoral^{TRADEMARK}

(ketoconazole) (tablets)

over 3 million
prescriptions
world-wide:

the new beginning
in antifungal therapy.



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but problematic fungal infections

can now be treated effectively *and* conveniently. Typically, in recurrent *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.

Full prescribing information available on request:



JANSSEN
PHARMACEUTICA

the drug discovery company

B-2340 Beerse, Belgium

Prescribing information

Presentation: white, flat, half-scored, uncoated tablets marked "Janssen" on one side and "K 200" on the reverse. Each tablet contains 200 mg ketoconazole.

Uses: Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in at-risk patients. In children, systemic mycoses and severe local infections where previous topical treatment has failed.

Side-effects, precautions, contra-indications: contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole; these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A, results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long-term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynaecomastia has been reported.




...the most effective life

SURG

potency in a drink

lipoic acid



Immunology

Lars Hanson *and* Hans Wigzell

This compact textbook gives complete coverage of all aspects of immunology, scientific and clinical in *one* volume. Many helpful drawings and photographs illustrate this complex subject. Students of medicine and bioscience will find a secure base on which to develop their interest in this text.

September 1985 320pp 0 407 00372 X £9.95

Epilepsies of Childhood

Second Edition

Niall V O'Donohoe

A thorough up to date account of childhood epilepsies emphasizing new diagnostic techniques and drug methods.

May 1985 288pp 0 407 00272 3 £27.50

Infections in Current Medical Practice

Edited by

Daniel Reid, Norman R Grist *and* Ian W Pinkerton

A multidisciplinary approach drawing on clinical microbiological and epidemiological expertise, for a comprehensive review of infectious diseases.

October 1985 224pp 0 407 00355 X £17.50 approx

Presentations in Primary Care

An illustrated introduction to patient management

J D E Knox

The 36 presentations of common problems presenting in the surgery are supplemented by questions and answers and a guide to further reading.

September 1985 144pp 0 407 00354 1 £9.95

Orthopaedic Disorders in General Practice

Richard L M Newell *and* Julian G Turner

A practical clinical manual on the diagnosis and management of common orthopaedic disorders.

July 1985 144pp 0 407 00392 4 £8.95

Order from your local bookseller or in case of difficulty from



Butterworths

Borough Green, Sevenoaks, Kent TN15 8PH

ADVANCES IN ECHO/DOPPLER 1985

The British Institute of Radiology
36 Portland Place, London W1N 3DG
A One Day Meeting
4 November 1985

This course is intended to provide a comprehensive survey of the present role of doppler in the assessment of cardiac disease plus an update on developments in cross-sectional imaging techniques.

Topics and speakers:

Normal doppler examination—Introduction; Normal doppler examination (N Wilson, Leeds); Assessment of valve gradients (J Gibbs, Leeds); Assessment of sub valve gradients (G Sutherland, Southampton); Valve regurgitation (T Skaerpe, Trondheim); Intracardiac shunting (N Wilson, Leeds); Assessment of prosthetic valves (G Leech, London); Doppler in paediatric cardiology (A Huston, Glasgow); Colour encoded doppler (J Roelandt, Rotterdam); Cardiac output (T Skaerpe, Trondheim).

Non invasive assessment of cardiac disease: Current status—Valvular disease: a physician's view (R Hall, Newcastle); a surgeon's view (D Shore, Southampton); Myocardial ischaemia/infarction (J Roelandt, Rotterdam); Paediatric cardiology (G Sutherland, Southampton).

Advances in cross sectional imaging—The role of trans-oesophageal echocardiography (P Hanrath, Hamburg); Intraoperative echocardiography (E Gussenhoven, Rotterdam); Contrast echo-new contrast agents potential role (R Erbel, Mainz).

Course Fee: £50

Course organiser:

Dr G Sutherland

Details from:

**Dr G Sutherland, Southampton General Hospital,
Cardiac Unit, Tremona Road, Southampton**

THE ROYAL COLLEGE OF SURGEONS OF EDINBURGH THE LISTER LECTURE

will be delivered by

John Wallwork Esq FRCSEd

Lister Professor 1985

Papworth Hospital, Cambridge

on

**"Heart-lung transplantation—
the development of a successful clinical programme"**

in the Hall of the College on

Thursday 31 October 1985 at 4.30 pm

This Lecture is open to Postgraduate Students

PROCEDURES IN PRACTICE

An illustrated step-by-step guide for doctors making their first attempts at the procedures commonly used in hospital practice. The articles explain the techniques in detail and give indications and contraindications for a range of tasks from setting up a drip to aspirating bone marrow.


*Price: Inland £4.50; Abroad £7.00; USA \$13.00
(BMA members: Inland £4.00; Abroad £6.50;
USA \$12.00). Despatched by air abroad.*

**BRITISH MEDICAL JOURNAL, BMA House,
Tavistock Square, London WC1H 9JR,
or any leading bookseller**

NO-SPA®

spasmolytic (Drotaverine)

tablets,
ampoules



Potent antispasmodic for relaxation
of smooth muscles

No-Spa is
—more potent than papaverine
—non toxic
—well absorbed from gastro
intestinal tract

No-Spa
—acts directly on hyper-tonic
smooth muscles
—does not possess anticholinergic
property

No-Spa has
—rapid onset of action
—minimal minor side effect
—high tolerance

Indications
—smooth muscle spasm colics of any origin
for short and long term therapy
—of gastrointestinal biliary and urogenital
spastic conditions, dysmenorrhoea
peripheral vascular disorders, coxarthrosis
coronary insufficiency, angina pectoris

Produced by Chinoin Pharmaceutical
and Chemical Works Ltd — Budapest — Hungary

Exported by
Medimpex Hungarian Trading Company
for Pharmaceutical Products
Budapest — Hungary

THE CARDIOPROTECTIVE CORONARY THERAPEUTIC AGENT ADALAT.

THE MODERN COMPREHENSIVE DRUG THERAPY OF CORONARY HEART DISEASE.



Indications: Treatment and prophylaxis of acute and chronic coronary insufficiency (especially angina pectoris, postinfarction syndrome). **Side effects:** Adalat is well tolerated. Side effects occur rarely. They are more common at the beginning of treatment, usually transient, and, in most cases, mild. Occasionally there can be headache, facial flush, heat sensation, dizziness, nausea and tiredness. Extensive biochemical studies did not reveal any abnormal values which could have been ascribed to the drug. **Contraindication:** Pregnancy. **Precaution:** Adalat can enhance or supplement the action of hypotensive preparations and β -blocking agents. Therapy with cardiac glycosides can be initiated or continued in association with Adalat treatment. Incompatibility with other drugs has not been found. **Dosage and administration:** In longterm treatment the capsule is usually swallowed whole with a little liquid. The average daily dose is 3 x 1 capsule, in special cases up to 3 x 2 capsules. In these patients the interval between the individual doses should not be less than two hours. In case of imminent anginal attack, a rapid onset of action is achieved by biting the capsule. **Composition:** One capsule contains 10 mg 1,4-dihydro-2,6-dimethyl-4-(o-nitrophenyl)-pyridine-3,5-dicarboxylic acid dimethyl ester (nifedipine). **Presentation:** Box of 30 or 50 capsules.

Bayer Germany

THE CARDIOPROTECTIVE CORONARY THERAPEUTIC AGENT



E 4/043

